Age: 79.0
Sex: M
Vaccine: COVID19, UNK
Symptoms: Condition aggravated, Epistaxis
Clinical narrative: Nose bleeds/ worsened; Nose bleeds/ worsened; This is a spontaneous report from a contactable consumer (the patient). A 79-year-old male patient received the first dose and second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), on 24Feb2021 (lot number EN6198) in the right arm, and on 20Mar2021 (lot number EP7534) (unsure which arm), respectively, both via an unspecified route of administration (at the age of 79-years-old), as a single dose for COVID-19 immunization; and apixaban (ELIQUIS) film-coated tablet, oral from an unspecified date (lot number 1743875, expiration date Feb2023), at 5 mg, twice a day as blood thinner. The patient's medical history included: chronic lymphoma leukemia from 2006- he is presently MRD negative, cardiomyopathy, alcohol ablation- where they go in through the groin and shoot alcohol to shrink the size of the heart to kill the fat around the heart. There were no concomitant medications. In Feb2021, after the first dose, the patient experienced nose bleeds. The patient never had nose bleeds before until after getting the first dose and was having more since getting the second dose. He has had two in one day. He was asking if the vaccine causes nose bleeds with taking a blood thinner. The nose bleeds have been more frequent. The nose bleeds were reported as worsened. The nose bleeds did not require an emergency room or physician office visit. The action taken in response to nose bleeds/ worsened for apixaban was unknown. The outcome of nose bleeds/ worsened was not recovered.  Follow-up (26Mar2021): This is a follow up spontaneous report from a contactable consumer based on information received by Pfizer from US-BRISTOL-MYERS SQUIBB (manufacturer control number US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-031555), license party for apixaban (ELIQUIS).  This case was received via Pfizer Inc (Reference number: 2021339514) on 26-Mar-2021 and was forwarded to BMS on 30-Mar-2021. This spontaneous case was reported by a consumer and describes the occurrence of EPISTAXIS (Nose Bleeds) in 79-year-old male patient who received apixaban (Eliquis) film-coated tablet (batch no. 1743875) for an unknown indication. CO-SUSPECT PRODUCTS included Covid-19 Vaccine for COVID-19 immunisation. The patient's past medical history included Chronic lymphoid leukemia (He is presently MRD negative) in 2006, Cardiomyopathy and Alcohol septal ablation (where they go in through the groin and shoot alcohol to shrink the size of the heart to kill the fat around the heart). On an unknown date, the patient started Eliquis (batch no. 1743875) (Oral), 5 milligram twice a day. On 24-Feb-2021, the patient started Covid-19 Vaccine (unknown route). On an unknown date, the patient experienced EPISTAXIS (Nose Bleeds). The action taken with Eliquis(Oral) was unknown. At the time of the report, EPISTAXIS did not resolve. For Eliquis(Oral), the reporter did not provide any causality assessments. The reporter stated that he never had nose bleeds before until after getting the first dose and was having more since getting the second dose. He has had two in one day. He was asking if the vaccine caused nose bleeds with taking a blood thinner. The nose bleeds have been more frequent. He received he first dose on 24-Feb-2021 and the second dose on 20-Mar-2021. Event nose bleeds did not require a visit to emergency room or physician office. Relevant Tests: none.